Table 1.
Study group demographics
| Group | Study population | Total N | Mean age ± SD | Female | |
|---|---|---|---|---|---|
| N | % | ||||
| LBD-NP | Low | 263 | 80.84 ± 11.13 | 128 | 48.67 |
| Intermediate | 287 | 79.63 ± 10.33 | 163 | 56.79 | |
| High | 423 | 78.04 ± 7.92 | 268 | 63.36 | |
| Combined LBD-NP | 973 | 79.27 ± 9.66 | 559 | 57.45 | |
| PSP | PSP series 1 | 230 | 74.8 ± 7.06 | 105 | 45.65 |
| PSP series 2 | 810 | 75.47 ± 7.45 | 376 | 46.42 | |
| Combined PSP | 1040 | 75.32 ± 7.37 | 481 | 46.25 | |
| Controls | 3351 | 80.6 ± 7.1 | 1844 | 55.03 | |
All LBD-NP and PSP participants had neuropathologic diagnosis. Controls had either clinical or neuropathologic diagnosis. “Combined LBD-NP” refers to the combined group of LBD-NP patients from all sub-categories. The sub-categories of “High”, “Intermediate”, or “Low” refers to the likelihood of diagnosing typical clinical DLB-CL based on the 2017 DLB-CL Consortium neuropathologic criteria [17]. All control and a subset of 230 PSP (series 1) cases were genotyped in our prior study [8]. All LBD-NP and an additional 810 PSP cases (series 2) were genotyped in this study
PSP progressive supranuclear palsy, LBD-NP Lewy body disease, neuropathologic diagnosis